529 related articles for article (PubMed ID: 16390401)
1. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Shah T; Lai WK; Gow P; Leeming J; Mutimer D
Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
[TBL] [Abstract][Full Text] [Related]
2. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation.
Singhal S; Ellis RW; Jones SG; Miller SJ; Fisher NC; Hastings JG; Mutimer DJ
Liver Transpl; 2000 Sep; 6(5):588-95. PubMed ID: 10980058
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.
Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
Pediatr Transplant; 1997 Nov; 1(2):124-9. PubMed ID: 10084772
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Kelsey SM; Goldman JM; McCann S; Newland AC; Scarffe JH; Oppenheim BA; Mufti GJ
Bone Marrow Transplant; 1999 Jan; 23(2):163-8. PubMed ID: 10197802
[TBL] [Abstract][Full Text] [Related]
6. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
8. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
Muñoz P; Guinea J; Narbona MT; Bouza E
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
[TBL] [Abstract][Full Text] [Related]
9. [Invasive fungal infections in liver transplant recipients: analysis of 21 cases].
Miguélez M; Lumbreras C; Herrero JA; Aguado JM; del Palacio A; Colina F; Gómez R; Lizasoain M; Moreno E; Rodríguez-Noriega A
Med Clin (Barc); 1998 Mar; 110(11):406-10. PubMed ID: 9608495
[TBL] [Abstract][Full Text] [Related]
10. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
[TBL] [Abstract][Full Text] [Related]
12. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
Reed A; Herndon JB; Ersoz N; Fujikawa T; Schain D; Lipori P; Hemming A; Li Q; Shenkman E; Vogel B
Liver Transpl; 2007 Dec; 13(12):1743-50. PubMed ID: 18044769
[TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
[TBL] [Abstract][Full Text] [Related]
14. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
Hellinger WC; Bonatti H; Yao JD; Alvarez S; Brumble LM; Keating MR; Mendez JC; Kramer DJ; Dickson RC; Harnois DM; Spivey JR; Hughes CB; Nguyen JH; Steers JL
Liver Transpl; 2005 Jun; 11(6):656-62. PubMed ID: 15915482
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
17. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
[TBL] [Abstract][Full Text] [Related]
18. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
19. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
20. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
